Analytical Data
-
基因名
BCL11B
- Application
-
别名
B-cell CLL/lymphoma 11B (COUP-TF-interacting protein 2) (Radiation-induced tumor suppressor gene 1 protein) (hRit1) (BCL-11B) (CTIP2) (RIT1)
-
种属
Human
-
表达系统
E. coli
-
标签
N- His & C- Myc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9C0K0
-
表达区间
387-823aa
-
分子量
53.7 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BCL11B, a member of the BCL11 family of proteins, plays a crucial role in the regulation of gene expression during the development of the immune system and the central nervous system. It is predominantly expressed in T cells and certain neuronal lineages, indicating its involvement in lineage commitment and differentiation. Research has shown that BCL11B acts as a transcriptional repressor, modulating the expression of genes associated with T cell development and function. Dysregulation of BCL11B has been implicated in various diseases, including autoimmune disorders and cancers, highlighting its potential as a therapeutic target. Recent studies have focused on the creation of recombinant BCL11B proteins to elucidate its functional mechanisms and interactomes. By employing techniques such as mass spectrometry and co-immunoprecipitation, researchers aim to identify BCL11B's protein partners and understand how its interactions influence cellular processes. The establishment of a reliable recombinant BCL11B protein system not only facilitates structural and functional studies but also paves the way for drug development aimed at modulating its activity in pathological contexts. As the BCL11B research landscape continues to evolve, understanding its complex regulatory networks will enhance our comprehension of immune and neuronal development, providing insights into targeted therapies for related diseases.
